Arch Biopartners Inc is a developer of a therapeutic pipeline designed to address acute kidney injury (AKI) and chronic kidney disease (CKD) by targeting inflammation- and toxin-related kidney damage. The group offers mechanism-based treatments, enabling patients suffering from both acute and chronic kidney conditions to benefit from novel, targeted therapies that address unmet medical needs in kidney care.